Text Size
3 studies found for:    21220472 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
Condition: Metastatic Non-squamous Non Small Cell Lung Cancer
Interventions: Drug: CBP501 + Cisplatin + Pemetrexed;   Drug: Cisplatin + Pemetrexed
2 Completed Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
Conditions: Malignant Pleural Mesothelioma;   Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501;   Drug: pemetrexed and cisplatin
3 Completed Phase I Clinical and Pharmacokinetic (PK) Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors
Conditions: Cancer;   Solid Tumors
Intervention: Drug: CBP501 and Cisplatin
To Top

† Indicates status has not been verified in more than two years